During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including ...

Cancers that were once considered incurable now have new treatment options. Among these innovations are CAR-T (chimeric ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

CAR T-cell therapy is a one-time intensive treatment that could potentially lead to a long remission, where Tec-Dara is an ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

There are now two very powerful but very different approaches that can be considered as early as first relapse for patients ...

Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...

The combined use of oncovaccines and CAR-T-cell therapy does not yet allow accurate prediction of the duration of remission in patients. On April 7, an oncologist at the Sberbank Health medical ...